Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6

QR Code

Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6

Giant cell arteritis (GCA) and polymyalgia rheumatica (RPM) are immune-mediated rheumatic disease (IMRDs), which typically develop in people over 50 years of age. Currently, GCA and PMR are considered within a single complex autoimmune-autoinflammatory pathology, defined as “GCA-PMR spectrum disease...

Full description

Saved in:

Bibliographic Details
Main Authors:	Evgeny L. Nasonov, Azamat M. Satybaldyev, Elvira N. Otteva, Tatiana V. Beketova, Andrey A. Baranov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2024-09-01
Series:	Научно-практическая ревматология
Subjects:	giant cell arteritis polymyalgia rheumatica interleukin 6 interleukin 6 inhibitors tocilizumab
Online Access:	https://rsp.mediar-press.net/rsp/article/view/3600
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases
by: Alexey D. Meshkov, et al.
Published: (2024-09-01)

EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01)

The evolution of diagnosis of polymyalgia rheumatica
by: A. M. Satybaldyev
Published: (2019-12-01)

INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01)

POLYMYALGIA RHEUMATICA
by: A. M. Satybaldyev, et al.
Published: (2018-05-01)

The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)
by: V. N. Antipova, et al.
Published: (2021-01-01)

The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy
by: E. L. Nasonov, et al.
Published: (2024-12-01)

REVIEW OF RECOMMENDATIONS FOR THE MANAGEMENT OF POLYMYALGIA RHEUMATICA (ACR/EULAR 2015)
by: M. T. Vatutin, et al.
Published: (2016-03-01)

International guidelines for the management of giant cell arteritis and polymyalgia rheumatica: The 2015 results
by: T. V. Beketova, et al.
Published: (2016-10-01)

Clinical manifestations and prognosis of giant cell arteritis: A retrospective cohort study
by: E. E. Filatova, et al.
Published: (2024-01-01)

CURRENT VIEW OF HORTON'S DISEASE: ANALYSIS OF ITS CASES IN THE KHABAROVSK TERRITORY
by: E. N. Otteva, et al.
Published: (2011-06-01)

Damage to extracranial arteries in giant cell arteritis according to PET/CT
by: E. E. Filatova, et al.
Published: (2023-03-01)

Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
by: G. M. Koilubaeva, et al.
Published: (2022-05-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01)

Onset of multiple myeloma with rheumatic polymyalgia
by: E. R. Israelyan, et al.
Published: (2019-12-01)

Polymyalgia rheumatica - risk factors, pathogenesis, diagnostic methods, treatment - new literature reports
by: Anita Warzocha, et al.
Published: (2025-07-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
by: E. L. Nasonov, et al.
Published: (2018-01-01)

Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case Reports
by: Ciro Manzo, et al.
Published: (2025-04-01)

New areas of the pharmacotherapy of rheumatic diseases are inhibition of interleukin-6 and interleukin-17
by: Evgeny Lvovich Nasonov
Published: (2013-10-01)

Giant cell arteritis. Part III. New trends in its treatment (role of genetically engineered drugs)
by: Azamat Makhmudovich Satybaldyev
Published: (2013-03-01)

PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS
by: L. P. Ananyeva
Published: (2016-02-01)

Effectiveness and safety of TNF-α inhibitors and il-6 pathway antagonists for refractory Takayasu arteritis
by: V. E. Logina, et al.
Published: (2024-12-01)

Giant cell arteritis. Part I. Terminology, classification, clinical manifestations, diagnosis
by: Azamat Makhmudovich Satybaldyev
Published: (2012-09-01)

Giant cell arteritis. Part II. Treatment
by: Azamat Makhmudovich Satybaldyev
Published: (2012-12-01)

Role of interleukin-6 in the development of atherosclerosis in rheumatoid arthritis
by: Elena Vasilyevna Udachkina, et al.
Published: (2013-10-01)

The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
by: E. L. Nasonov, et al.
Published: (2019-11-01)

Comparison of different treatment modalities of tocilizumab in children with systemic juvenile idiopathic arthritis
by: M. M. Kostik, et al.
Published: (2013-09-01)

Efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus: A case report and a review of literature
by: S. K. Solovyev, et al.
Published: (2017-09-01)

Cardiometabolic risk factors and their relationship with the interleukin-6 receptor gene polymorphism (rs2228145) in patients with hypertrophic cardiomyopathy
by: T. G. Bezhanishvili, et al.
Published: (2020-11-01)

Detection of interleukin-6 and interleukin-8 in serum from women with recurrent spontaneous abortion
by: Baghdad Science Journal
Published: (2010-09-01)

Evaluation of the efficiency and safety of tocilizumab therapy in patients with systemic-onset juvenile idiopathic arthritis: results of a retrospective follow-up
by: M. M. Kostik, et al.
Published: (2018-01-01)

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study
by: Mikhail M. Kostik, et al.
Published: (2017-06-01)

The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series
by: Eric Daniel Tenda, et al.
Published: (2021-10-01)

Treatment for rheumatic polymyalgia
by: Azamat Makhmudovich Satybaldyev
Published: (2013-03-01)

A Systematic Review with Meta-Analysis and Indirect Comparison of the Effectiveness of COVID-19 Anti-Interleukin Therapy
by: Yu. M. Gomon, et al.
Published: (2023-07-01)

Giant Cell Arteritis
by: E. V. Shevchenko, et al.
Published: (2025-01-01)

Clinical picture of polymialgia rheumatica in Habarovsk region’s residents
by: T. Y. Kocherova,, et al.
Published: (2016-05-01)

Difficulties in the Diagnosis and Management of Patients with Takayasu’s Arteritis: A Description of a 5-Year Clinical Follow-Up
by: A. V. Petrov, et al.
Published: (2023-10-01)

DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE
by: P. A. Shesternya, et al.
Published: (2019-09-01)